利索-全球专利检索

  1. 登录
  2. 注册

搜索结果

37 条记录 (耗时 0.025 秒)

    Prostate cancer glycan markers and autoantibody signatures
    3.
    发明授权
    Prostate cancer glycan markers and autoantibody signatures 有权
    前列腺癌聚糖标记物和自身抗体签名

    公开(公告)号：US07981625B2

    公开(公告)日：2011-07-19

    申请号：US12421964

    申请日：2009-04-10

    申请人： Denong Wang ,  Leonore A. Herzenberg ,  Donna M. Peehl ,  Leonard A. Herzenberg

    发明人： Denong Wang ,  Leonore A. Herzenberg ,  Donna M. Peehl ,  Leonard A. Herzenberg

    IPC分类号： G01N33/53

    CPC分类号： C40B40/12 ,  C07K16/3069 ,  G01N33/57434 ,  G01N2333/42 ,  G01N2400/10

    摘要： Disclosed are methods for probing the immunogenic sugar moieties of prostate cancer cells. The methods detect a number of glyco-epitopes that are highly and differentially expressed among prostate cancers of various Gleason grades. The glyco-epitopes exist on the surfaces of prostate cells. The methods also comprise the detection of autoantibodies in prostate cancer subjects. The antibodies bound to a glyco-motif of N-glycans that is normally “cryptic.” This target is highly expressed in prostate cancers. Lectins and antibodies that detect these glyco-epitopes that expressed in prostate cancer tissues include Euonymus europaeus lectin (EEL); Psophocarpus Tetragonolobus Lectin-I (PTL-I); Griffonia Simplicifolia Lectin-I-A4 (GSL-I-A4); Griffonia Simplicifolia Lectin-I-B4 (GSL-I-B4); Sambucus nigra I agglutinin (SNA-I; Phaseolus vulgaris-L (PHA-L; Galanthus nivalis agglutinin (GNA); Narcissus pseudonarcissus agglutinin (NPA); Artocarpus integrifolia agglutinin (Jacalin); and mAb TM10 (IgM).

    摘要翻译： 公开了用于探测前列腺癌细胞的免疫原性糖部分的方法。 该方法检测了在各种Gleason等级的前列腺癌中高度差异表达的糖基表位。 糖表位存在于前列腺细胞表面。 该方法还包括检测前列腺癌受试者中的自身抗体。 抗体结合通常是“神秘的”的N-聚糖的糖基序。 这个目标在前列腺癌中高度表达。 检测在前列腺癌组织中表达的这些糖表位的凝集素和抗体包括卫矛神经凝集素（EEL）; 茯苓四倍体凝集素-I（PTL-I）; Griffonia Simplicifolia果胶-I-A4（GSL-I-A4）; Griffonia Simplicifolia凝集素-I-B4（GSL-I-B4）; 黑曲霉I凝集素（SNA-1）; 菜豆提取物（PHA-L）; 山茱萸凝集素（GNA）; 水仙假水凝素（NPA）; Artocarpus integrifolia凝集素（Jacalin）; 和mAb TM10（IgM）。

    Prostate Cancer Glycan Markers and Autoantibody Signatures
    5.
    发明申请
    Prostate Cancer Glycan Markers and Autoantibody Signatures 有权
    前列腺癌糖蛋白标记和自身抗体签名

    公开(公告)号：US20090258792A1

    公开(公告)日：2009-10-15

    申请号：US12421964

    申请日：2009-04-10

    申请人： Denong Wang ,  Leonore A. Herzenberg ,  Donna M. Peehl ,  Leonard A. Herzenberg

    发明人： Denong Wang ,  Leonore A. Herzenberg ,  Donna M. Peehl ,  Leonard A. Herzenberg

    IPC分类号： C40B30/04 ,  C40B30/06 ,  C40B40/12

    CPC分类号： C40B40/12 ,  C07K16/3069 ,  G01N33/57434 ,  G01N2333/42 ,  G01N2400/10

    摘要： Disclosed are methods for probing the immunogenic sugar moieties of prostate cancer cells. The methods detect a number of glyco-epitopes that are highly and differentially expressed among prostate cancers of various Gleason grades. The glyco-epitopes exist on the surfaces of prostate cells. The methods also comprise the detection of autoantibodies in prostate cancer subjects. The antibodies bound to a glyco-motif of N-glycans that is normally “cryptic.” This target is highly expressed in prostate cancers. Lectins and antibodies that detect these glyco-epitopes that expressed in prostate cancer tissues include Euonymus europaeus lectin (EEL); Psophocarpus Tetragonolobus Lectin-I (PTL-I); Griffonia Simplicifolia Lectin-I-A4 (GSL-I-A4); Griffonia Simplicifolia Lectin-I-B4 (GSL-I-B4); Sambucus nigra I agglutinin (SNA-I; Phaseolus vulgaris-L (PHA-L; Galanthus nivalis agglutinin (GNA); Narcissus pseudonarcissus agglutinin (NPA); Artocarpus integrifolia agglutinin (Jacalin); and mAb TM10 (IgM).

    摘要翻译： 公开了用于探测前列腺癌细胞的免疫原性糖部分的方法。 该方法检测了在各种Gleason等级的前列腺癌中高度差异表达的糖基表位。 糖表位存在于前列腺细胞表面。 该方法还包括检测前列腺癌受试者中的自身抗体。 抗体结合通常是“神秘的”的N-聚糖的糖基序。 这个目标在前列腺癌中高度表达。 检测在前列腺癌组织中表达的这些糖表位的凝集素和抗体包括卫矛神经凝集素（EEL）; 茯苓四倍体凝集素-I（PTL-I）; Griffonia Simplicifolia果胶-I-A4（GSL-I-A4）; Griffonia Simplicifolia凝集素-I-B4（GSL-I-B4）; 黑曲霉I凝集素（SNA-1）; 菜豆提取物（PHA-L）; 山茱萸凝集素（GNA）; 水仙假水凝素（NPA）; Artocarpus integrifolia凝集素（Jacalin）; 和mAb TM10（IgM）。

    N-acetylcysteine compositions and methods for the treatment and prevention of drug toxicity
    7.
    发明授权
    N-acetylcysteine compositions and methods for the treatment and prevention of drug toxicity 有权

    公开(公告)号：US06566401B2

    公开(公告)日：2003-05-20

    申请号：US09833228

    申请日：2001-04-11

    申请人： Leonard A. Herzenberg ,  Leonore A. Herzenberg ,  Stephen C. De Rosa ,  James Andrus

    发明人： Leonard A. Herzenberg ,  Leonore A. Herzenberg ,  Stephen C. De Rosa ,  James Andrus

    IPC分类号： A61K31195

    CPC分类号： A61K31/7072 ,  A61K31/198

    摘要： The invention provides pharmaceutical compositions for the treatment or prevention of the toxic effects of therapeutic agents and methods of treating or preventing such toxicity using a toxicity reducing amount of N-acetylcysteine either alone or in combination with a therapeutically effective amount or, to achieve its therapeutic advantages, an amount larger than what is customarily given as a therapeutically effective amount, of a therapeutic agent. The invention also provides pharmaceutical compositions for the treatment or prevention of the toxic effects of therapeutic agents and methods of treating or preventing such toxicity using a toxicity reducing amount of N-acetylcysteine either alone or in combination with a therapeutically effective amount or, to achieve its therapeutic advantages, an amount larger than what is customarily given as a therapeutically effective amount, of a therapeutic agent whose side effects are made worse by increased oxidative stress or treatment related decreases in subject cysteine/glutathione levels or are otherwise relieved by administration of NAC.

    N-acetylcysteine compositions and methods for the treatment and prevention of drug toxicity
    8.
    发明授权
    N-acetylcysteine compositions and methods for the treatment and prevention of drug toxicity 有权
    N-乙酰半胱氨酸组合物和用于治疗和预防药物毒性的方法

    公开(公告)号：US07723389B2

    公开(公告)日：2010-05-25

    申请号：US10287175

    申请日：2002-11-04

    申请人： Leonard A. Herzenberg ,  Leonore A. Herzenberg ,  Stephen C. De Rosa ,  James Andrus

    发明人： Leonard A. Herzenberg ,  Leonore A. Herzenberg ,  Stephen C. De Rosa ,  James Andrus

    IPC分类号： A61K31/195 ,  A61K31/65 ,  A61K31/63 ,  A61K31/60 ,  A61K31/43 ,  A61K31/545

    CPC分类号： A61K31/7072 ,  A61K31/198

    摘要： The invention provides pharmaceutical compositions for the treatment or prevention of the toxic effects of therapeutic agents and methods of treating or preventing such toxicity using a toxicity reducing amount of N-acetylcysteine either alone or in combination with a therapeutically effective amount or, to achieve its therapeutic advantages, an amount larger than what is customarily given as a therapeutically effective amount, of a therapeutic agent. The invention also provides pharmaceutical compositions for the treatment or prevention of the toxic effects of therapeutic agents and methods of treating or preventing such toxicity using a toxicity reducing amount of N-acetylcysteine either alone or in combination with a therapeutically effective amount or, to achieve its therapeutic advantages, an amount larger than what is customarily given as a therapeutically effective amount, of a therapeutic agent whose side effects are made worse by increased oxidative stress or treatment related decreases in subject cysteine/glutathione levels or are otherwise relieved by administration of NAC.

    摘要翻译： 本发明提供用于治疗或预防治疗剂的毒性作用的药物组合物，以及使用毒性降低量的N-乙酰半胱氨酸单独或与治​​疗有效量组合治疗或预防此类毒性的方法，或实现其治疗 优点，其量大于通常给予治疗有效量的量的治疗剂。 本发明还提供了用于治疗或预防治疗剂的毒性作用的药物组合物，以及使用单独的或与治疗有效量组合使用的毒性降低量的N-乙酰半胱氨酸来治疗或预防此类毒性的方法，或者达到其 通过增加的氧化应激或治疗而使副作用变得更差的治疗剂的治疗优势大于通常给予治疗有效量的量，相关的受试者半胱氨酸/谷胱甘肽水平降低或通过施用NAC而缓解。

    Rapid assay for infection in neonates
    10.
    发明授权
    Rapid assay for infection in neonates 失效
    快速检测新生儿感染

    公开(公告)号：US06077665A

    公开(公告)日：2000-06-20

    申请号：US833677

    申请日：1997-04-08

    申请人： Erica E. Weirich ,  Ronald L. Rabin ,  Yvonne Maldonado ,  William E. Benitz ,  Leonore A. Herzenberg ,  Leonard A. Herzenberg

    发明人： Erica E. Weirich ,  Ronald L. Rabin ,  Yvonne Maldonado ,  William E. Benitz ,  Leonore A. Herzenberg ,  Leonard A. Herzenberg

    IPC分类号： G01N33/53 ,  C12Q1/02 ,  G01N33/569 ,  C12Q1/68

    CPC分类号： G01N33/56972 ,  G01N33/569 ,  G01N33/56988

    摘要： A rapid assay for infection in immunodeficient patients such as neonates or immunocompromised patients (e.g. HIV or transplant patients) allows diagnosis at initial evaluation, such that antibiotic treatment and confinement to an intensive care unit can be avoided for uninfected patients. The assay can be used for detecting bacterial, viral, or fungal colonization of the blood stream, cerebrospinal fluid (CSF), or urinary tract. The method is particularly useful for sepsis diagnosis. Polymorphonuclear leukocyte (PMN, neutrophil) CD11b (Mac-1, CR3) levels are measured by flow cytometry or laser scanning microscopy in low volume (0.1 ml) whole blood samples. A dual-laser FACS identifies neutrophils by FITC-conjugated anti-CD15 fluorescent antibodies, and identifies surface neutrophil CD11b marked with PE-conjugated anti-CD11b antibodies. Spontaneous upregulation of CD11b is prevented by handling samples at 4.degree. C. or adding a stabilizing compound such as anti-CD14 antibody or adenosine to the samples. A kit comprises calibration markers such as CD11b-coated microspheres for calibrating the device used for analysis according to diagnosis threshold(s).

    摘要翻译： 免疫缺陷患者如新生儿或免疫受损患者（例如HIV或移植患者）中的感染的快速测定允许在初始评估时进行诊断，从而可以避免对未感染患者的抗生素治疗和对重症监护病房的限制。 该测定法可用于检测血流，脑脊液（CSF）或尿道的细菌，病毒或真菌定植。 该方法对败血症诊断特别有用。 通过流式细胞术或激光扫描显微镜在低体积（0.1ml）全血样品中测量多形核白细胞（PMN，嗜中性粒细胞）CD11b（Mac-1，CR3）水平。 双激光FACS通过FITC缀合的抗CD15荧光抗体识别嗜中性粒细胞，并鉴定用PE缀合的抗CD11b抗体标记的表面嗜中性粒细胞CD11b。 通过在4℃处理样品或向样品中加入稳定化合物如抗-CD14抗体或腺苷来防止CD11b的自发上调。 试剂盒包括诸如CD11b涂覆的微球的校准标记，用于根据诊断阈值校准用于分析的装置。